Leading drugmaker Sun Pharma is doubling down on its specialty portfolio, launching new products and ramping up ...

Discover key Royalty Pharma Q3 2025 earnings insights—double-digit growth, new acquisitions, and raised guidance for investors.

Investors seeking momentum may have iShares U.S. Pharmaceuticals ETF IHE on radar now. The fund recently hit a new 52-week high. Shares of IHE are up approximately 29.6% from their 52-week low of $58.

Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet, Dow Jones Stock Movers: Gainers, ...

On November 3, 2025, Privium Fund Management B.V. reported selling 138,263 shares of Arrowhead Pharmaceuticals ( ARWR 1.57%) ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to a broad basket of industry-leading biotech equities. The fund's strategy ...

Industry leaders say uncertainty in funding, clinical development and manufacturing is driving companies to embrace digital transformation, streamlined operations and strategic partnerships to ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

Oct 15 (Reuters) - Volatility Shares, an issuer of exchange-traded funds, filed on Wednesday to launch a total of 27 highly leveraged ETFs, including the first-ever proposed 5x ETF for the U.S. market ...